Agreements to provide affordable lenacapavir

Agreements to provide affordable lenacapavirOn Sept 24, 2025, two agreements were announced between funders and generic drug manufacturers.The two agreements ensured the availability of groundbreaking twice-yearly injectable HIV pre-exposure prophylaxis (PrEP) drug lenacapavir at an annual price of US$40 per patient in 120 low-income and middle-income countries (LMICs) from 2027.In Oct 2, 2024, Gilead Sciences (CA, USA), the manufacturer of lenacapavir, declared that it had signed licensing agreements with six generic drug manufacturers, including Dr. Reddy's Laboratories (Hyderabad, India) and Hetero Labs (Hyderabad, India), to manufacture and sell the affordable and generic versions of lenacapavir for 120 countries (mainly LMICs) with high HIV incidence and limited resources.The countries included Ethiopia, Botswana, Eswatini, Malawi, Mozambique, Namibia, Rwanda, Zambia, and Viet Nam.Unitaid (Geneva, Switzerland), the